找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 20161st edition Springer International Publishing Switzerland 2016 Chronic myeloid leukaem

[復(fù)制鏈接]
樓主: Garfield
21#
發(fā)表于 2025-3-25 07:04:04 | 只看該作者
22#
發(fā)表于 2025-3-25 10:43:44 | 只看該作者
23#
發(fā)表于 2025-3-25 12:16:27 | 只看該作者
24#
發(fā)表于 2025-3-25 16:43:04 | 只看該作者
https://doi.org/10.1007/978-3-030-34898-4n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
25#
發(fā)表于 2025-3-25 22:12:24 | 只看該作者
Franz Breuer,Petra Muckel,Barbara Dierisbe recommended for patients with a well matched donor and low risk transplant profile as early as possible. It is discouraged for patients with failed response to multiple TKIs and no matched donor. Close interaction between CML physicians and transplant centers facilitates such a targeted risk adapted approach.
26#
發(fā)表于 2025-3-26 01:20:34 | 只看該作者
,Gütekriterien und ethische Fragen,ost importance even for drug companies. It should be considered the future criterion to evaluate the success of clinical trials, especially if we want to take into account quality of life of patients and also the economic aspect..The question of cure in CML is now one of the major concerns and has to be considered in the management of the disease.
27#
發(fā)表于 2025-3-26 04:29:39 | 只看該作者
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia,n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
28#
發(fā)表于 2025-3-26 09:34:53 | 只看該作者
29#
發(fā)表于 2025-3-26 15:38:21 | 只看該作者
30#
發(fā)表于 2025-3-26 18:54:50 | 只看該作者
Response-Related Predictors of Survival in CML,h of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI, and for second-line TKI treatment as well.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 23:02
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
平安县| 尼勒克县| 安多县| 张家港市| 鄂伦春自治旗| 锦屏县| 城固县| 正阳县| 大安市| 牟定县| 漯河市| 五常市| 奉节县| 诸暨市| 崇州市| 昂仁县| 洞头县| 陆河县| 图木舒克市| 天全县| 汉川市| 宜川县| 乌审旗| 蒙阴县| 海口市| 昌江| 门源| 宣化县| 盘山县| 五常市| 磴口县| 巴林左旗| 兴化市| 和林格尔县| 彰化县| 准格尔旗| 汽车| 峨山| 榕江县| 通山县| 梧州市|